Details of the Drug-Related molecule(s) Expression Atlas
General Information of Drug (ID: DMDTRZ2)
Drug Name | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
91533-01-6; 2-morpholin-4-yl-N-(4-sulfamoylphenyl)acetamide; CHEMBL180943; Sulfanilamide, N4-(alpha-morpholinoacetyl)-; 2-(morpholin-4-yl)-N-(4-sulfamoylphenyl)acetamide; N4-(alpha-Morpholinoacetyl)sulfanilamide; AE-848/36321029; 2-Morpholin-4-yl-N-(4-sulfamoyl-phenyl)-acetamide; AC1L47H0; SCHEMBL15798186; DTXSID70238616; MolPort-000-225-319; BDBM50157946; ZINC19901027; STL294445; AKOS001028531; MCULE-6306887577; ST086382; SR-01000467406; SR-01000467406-1; Z46180370; 4-Morpholineacetamide, N-(4-(aminosulfonyl)phenyl)-
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecule(s) Related to This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs
|
||||||||||||||||||||||||||||||||||||||||
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs | ||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue
The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue | ||||||||||||||||||||||||||||||||||||